New oral therapies for multiple sclerosis are starting to have their expected adverse effect on sales of Merck KGAA's best-selling injectable product Rebif (interferon beta-1a), whose sales markedly declined in the 2015 second quarter.
Although currency exchange rate tailwinds of 11.3% helped to maintain Rebif's reported sales at €461m in the quarter, without those...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?